Press Room

Press Clipping / Nov 25, 2024

Pharma company Hovione to double capacity at Cork site as part multi-million euro investment

Irish Examiner, 25 November 2024

Pharmaceutical contract development and manufacturing company Hovione has officially commissioned an expansion at its manufacturing facility in Ringaskiddy, Cork. 

Announcing the development on Monday, the multi-million euro investment almost doubles the capacity of Hovione’s spray drying facilities in Ireland and will create more than 20 new positions.

This manufacturing technology is especially important for inhalable therapies and oral medications with low bioavailability, enabling more effective treatments, the company said.

Deputising for the Mayor of the County of Cork, Cllr. Audrey Buckley said: “I am delighted to welcome this very significant investment and the creation of further highly skilled jobs in Cork today. 

"It reinforces Hovione’s commitment to the region and the innovative solutions it provides to the pharmaceutical industry in Ireland.” 

Michael McGrath, the European Commissioner-Designate for Democracy, Justice and the Rule of Law said: “This latest investment highlights the success of Hovione’s facility in Ringaskiddy, and underlines the continued resilience of Ireland’s pharmaceutical manufacturing sector.

"I am delighted that Hovione will be shortly welcoming new team members to this expanded facility, and I wish both them and Hovione every success”.

This latest investment builds on the momentum of the recently announced spray drying capacity expansion at the Company's East Windsor, New Jersey, site. 

Jean-Luc Herbeaux, Hovione´s Chief Executive said: “This newly opened facility further strengthens Hovione´s position as the global CDMO of choice for spray drying development and manufacturing services. 

"It also underscores our commitment to bringing first-in-class technology and world-leading manufacturing services to Irish shores. Ireland provides a superior environment for pharmaceutical manufacturing, and we are delighted to be a part of it.”

IDA chief executive Michael Lohan said the company has made a significant contribution both locally and nationally, adding: "I am pleased to be here today to mark another step on that journey. We warmly welcome Hovione’s commitment to investing in Cork and we wish them continued success.”

 

Read the full article on IrishExaminer.com

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026